JQ1

JQ1

Identifiers
IUPAC name (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3-a] [1,4]diazepin-6-yl)acetate
CAS Number	1268524-70-4  Y
PubChem CID	46907787
IUPHAR/BPS	7511
ChemSpider	26323622
UNII	1MRH0IMX0W
ChEBI	CHEBI:137113  Y
CompTox Dashboard (EPA)	DTXSID20155309
Chemical and physical data
Formula	C23H25ClN4O2S
Molar mass	456.99 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C
InChI InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1 Key:DNVXATUJJDPFDM-KRWDZBQOSA-N

JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma. ^[1] It was developed by the James Bradner laboratory at Brigham and Women's Hospital and named after chemist Jun Qi. The chemical structure was inspired by patent of similar BET inhibitors by Mitsubishi Tanabe Pharma. ^[2] Structurally it is related to benzodiazepines. While widely used in laboratory applications, JQ1 is not itself being used in human clinical trials because it has a short half life.

Efficacy in mouse models of cancer

Interest in JQ1 as a cancer therapeutic stemmed from its ability to inhibit BRD4 and BRD3, both of which form fusion oncogenes that drive NUT midline carcinoma. ^{[3] [4]} Subsequent work demonstrated that a number of cancers including some forms of acute myelogenous leukemia (AML), multiple myeloma (MM), and acute lymphoblastic leukemia (ALL) were also highly sensitive to BET inhibitors. ^{[5] [6]}

In other applications

JQ1 has also been investigated for other applications in the treatment of HIV infection, ^[7] as a male contraceptive, ^[8] and in slowing the progression of heart disease. ^[9]

JQ1 has been functionalized in numerous different studies of targeted protein degradation. For example, conjugation of JQ1 to phthalimide moieties such as that found in thalidomide recruits the E3 ubiquitin ligase cereblon (CRBN) to effect proteasomal degradation of BRD4. ^[10] Monovalent degraders based on functionalizing JQ1 have also been discovered. ^{[11] [12] [13] [14]}

Fusion of JQ1 to other molecules targeting specific genomic loci has been demonstrated to rewire transcription. ^{[15] [16]}

See also

• Male contraceptive
• CDD-2807
• TDI-11861
• YCT529

References

1. "Studies found for: bet inhibitor". ClinicalTrials.Gov. National Library of Medicine, National Institutes of Health, U.S. Department of Health and Human Services.
2. WO/2009/084693
3. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. (December 2010). "Selective inhibition of BET bromodomains". Nature. 468 (7327): 1067–73. Bibcode:2010Natur.468.1067F. doi:10.1038/nature09504. PMC   3010259 . PMID   20871596.
4. Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, West NH, et al. (April 2011). "Differentiation of NUT midline carcinoma by epigenomic reprogramming". Cancer Research. 71 (7): 2686–96. doi:10.1158/0008-5472.CAN-10-3513. PMC   3070805 . PMID   21447744.
5. Belkina AC, Denis GV (June 2012). "BET domain co-regulators in obesity, inflammation and cancer". Nature Reviews. Cancer. 12 (7): 465–77. doi:10.1038/nrc3256. PMC   3934568 . PMID   22722403.Shi J, Vakoc CR (June 2014). "The mechanisms behind the therapeutic activity of BET bromodomain inhibition". Molecular Cell. 54 (5): 728–36. doi:10.1016/j.molcel.2014.05.016. PMC   4236231 . PMID   24905006.
6. Da Costa D, Agathanggelou A, Perry T, Weston V, Petermann E, Zlatanou A, et al. (July 2013). "BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia". Blood Cancer Journal. 3 (7): e126. doi:10.1038/bcj.2013.24. PMC   3730202 . PMID   23872705.
7. Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, et al. (December 2012). "BET bromodomain inhibition as a novel strategy for reactivation of HIV-1". Journal of Leukocyte Biology. 92 (6): 1147–54. doi:10.1189/jlb.0312165. PMC   3501896 . PMID   22802445.
8. Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, et al. (August 2012). "Small-molecule inhibition of BRDT for male contraception". Cell. 150 (4): 673–84. doi:10.1016/j.cell.2012.06.045. PMC   3420011 . PMID   22901802.
9. Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, et al. (August 2013). "BET bromodomains mediate transcriptional pause release in heart failure". Cell. 154 (3): 569–82. doi:10.1016/j.cell.2013.07.013. PMC   4090947 . PMID   23911322.
10. Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, et al. (June 2015). "DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation". Science. 348 (6241): 1376–1381. doi:10.1126/science.aab1433. PMC   4937790 . PMID   25999370.
11. Blake RA (2019-07-01). "Abstract 4452: GNE-0011, a novel monovalent BRD4 degrader". Cancer Research. 79 (13_Supplement): 4452. doi:10.1158/1538-7445.AM2019-4452. ISSN   0008-5472.
12. Hsia O, Hinterndorfer M, Cowan AD, Iso K, Ishida T, Sundaramoorthy R, et al. (March 2024). "Targeted protein degradation via intramolecular bivalent glues". Nature. 627 (8002): 204–211. doi:10.1038/s41586-024-07089-6. PMC   10917667 . PMID   38383787.
13. Lim M, Cong TD, Orr LM, Toriki ES, Kile AC, Papatzimas JW, et al. (July 2024). "DCAF16-Based Covalent Handle for the Rational Design of Monovalent Degraders". ACS Central Science. 10 (7): 1318–1331. doi:10.1021/acscentsci.4c00286. PMC   11273451 . PMID   39071058.
14. Shergalis AG, Marin VL, Rhee DY, Senaweera S, McCloud RL, Ronau JA, et al. (February 2023). "CRISPR Screen Reveals BRD2/4 Molecular Glue-like Degrader via Recruitment of DCAF16". ACS Chemical Biology. 18 (2): 331–339. doi:10.1021/acschembio.2c00747. PMID   36656921.
15. Erwin GS, Grieshop MP, Ali A, Qi J, Lawlor M, Kumar D, et al. (December 2017). "Synthetic transcription elongation factors license transcription across repressive chromatin". Science. 358 (6370): 1617–1622. doi:10.1126/science.aan6414. PMC   6037176 . PMID   29192133.
16. Gourisankar S, Krokhotin A, Ji W, Liu X, Chang CY, Kim SH, et al. (August 2023). "Rewiring cancer drivers to activate apoptosis". Nature. 620 (7973): 417–425. doi:10.1038/s41586-023-06348-2. PMC   10749586 . PMID   37495688.